STOCK TITAN

EoCene develops Aramchol formulation with Barcode

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Eocene Ltd. (EOCN) said its wholly owned subsidiary Galmed Research & Development and Barcode Nanotech developed a new Aramchol lipid nanoparticle (LNP) formulation using Barcode’s tumor-targeting platform. Their ongoing collaborative research aims to redirect Aramchol’s biodistribution to the tumor microenvironment in liver and gastrointestinal cancers. Eocene described this as a potential way to target fibrosis in the tumor environment.

The company said the work builds on previously reported results for oral Aramchol: improvement in liver fibrosis in patients with NASH/MASH in the randomized, double-blind, placebo-controlled phase IIb ARREST trial and an open-label extension of the phase III ARMOR study. Barcode is applying its proprietary lipid library and in vivo, AI-based screening platform, including tumor-targeting LNP technology. Eocene said it is not aware of an approved therapy that targets fibrosis to remodel the tumor microenvironment.

tumor microenvironment (TME) medical
"target tumor microenvironment (TME)"
The tumor microenvironment (TME) is the immediate surrounding area of a tumor, including nearby cells, blood vessels, and supporting tissues that interact with the cancer cells. It plays a crucial role in how a tumor grows and spreads, much like how the environment around a plant influences its health and development. For investors, understanding the TME is important because it affects the success of treatments and innovations in cancer therapies, impacting the potential value of related biotech companies.
lipid nanoparticles (LNPs) technical
"lipid-based nanoparticles (LNPs)"
Lipid nanoparticles (LNPs) are tiny, fat‑like bubbles that package and protect fragile drug payloads such as genetic material so they can be delivered into cells. Think of them as microscopic shipping containers that control where and how a medicine arrives and is released in the body. Investors care because LNPs are a critical technology platform: their effectiveness, manufacturability, patent coverage and regulatory safety profile can determine a drug’s commercial success and production costs.
biodistribution medical
"redirect Aramchol’s biodistribution"
Biodistribution is the map of where a drug, vaccine, or diagnostic agent travels and accumulates inside the body after administration. Investors care because where a product ends up affects how well it works, what side effects it may cause, and whether regulators will approve it—similar to tracking dye in a plumbing system to find leaks or blockages; unexpected destinations can raise safety, cost, and market-adoption risks.
immune checkpoint Inhibitors medical
"current cancer therapies such as immune checkpoint Inhibitors"
Drugs that release the immune system’s natural “brakes,” allowing immune cells to recognize and attack cancer cells; imagine taking the safety off a guard dog so it can chase intruders. They matter to investors because they can become high-value treatments with large sales potential, but their commercial success depends on clinical trial results, regulatory approval, competition and side-effect management, which all affect a company’s valuation.
angiogenesis inhibitors medical
"and angiogenesis inhibitors"
antifibrotic effect medical
"enhance and accelerate the antifibrotic effect"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is EOCN developing with Barcode Nanotech?

Eocene and Barcode Nanotech developed a tumor-targeted Aramchol LNP formulation. Their ongoing research aims to redirect Aramchol’s biodistribution to the tumor microenvironment in liver and gastrointestinal cancers.

What has Eocene reported about oral Aramchol in liver fibrosis?

Eocene said oral Aramchol demonstrated improvement in liver fibrosis in patients with NASH/MASH in the phase IIb ARREST trial and an open-label extension of the phase III ARMOR study.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of November 2026

 

001-36345

(Commission File Number)

 

Eocene LTD.

(Exact name of Registrant as specified in its charter)

 

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

On November 16, 2026, Eocene Ltd. (the “Company”) issued a press release entitled “Eocene and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of Aramchol.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
99.1   Press Release, dated November 16, 2026.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Eocene Ltd.
     
Date: November 16, 2026 By: /s/ Allen Baharaff
    Allen Baharaff
    President and Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

Eocene and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of Aramchol

 

●A unique proprietary lipid nanoparticles (LNPs) novel formulation of Aramchol has been developed using FDA-approved Lipids.

 

●The novel formulation is designed to redirect Aramchol’s biodistribution to target tumor microenvironment (TME) in liver and GI tumors and selectively inhibit the activity of cells that drive fibrosis.

 

●By selectively targeting TME cells that drive fibrosis, the Aramchol LNP treatment could make immunotherapy and other standard of care liver and GI cancer therapies, work better for more patients with minimal toxicity.

 

Givatayim, Israel, November 16, 2026 – Eocene Ltd. (NASDAQ: EOCN) (“Eocene” or the “Company”) report today updates from its wholly owned subsidiary, Galmed Research & Development Ltd. (“Galmed”), ongoing collaborative research with Barcode Nanotech (“Barcode”). Based on Barcode’s proprietary tumor targeting delivery LNPs formulation platform, a novel Aramchol LNPs formulation was developed. The new LNP formulation aims to redirect Aramchol’s biodistribution to target tumor microenvironment (TME) in liver and GI tumors.

 

The TME is a complex network of immune cells, blood vessels and fibroblasts that interacts with cancer cells to facilitate tumor growth progression and hamper therapy responsiveness. While current cancer therapies such as immune checkpoint Inhibitors (Keytruda, Opdivo) and angiogenesis inhibitors (Avastin- anti-VEGF) address immune cells and blood vessels formation in TME, the Company is not aware of any approved therapy that targets fibrosis to remodel the TME.

 

As previously announced, in a randomized, double-blind, placebo-controlled phase IIb trial (ARREST) and an open label extension of a phase III study (ARMOR), orally formulated Aramchol demonstrated improvement in liver fibrosis in patients with NASH/MASH.

 

 

 

 

By employing the Barcode’s existing tumor-targeting LNP formulation, Galmed aims to enhance and accelerate the antifibrotic effect observed with the oral formulation by redirecting Aramchol’s biodistribution to target tumor microenvironment (TME).

 

Allen Baharaff, President and Chief Executive Officer of Eocene commented: “Liver and other cancers often arise in fibrotic tissue as a result of chronic disease. Fibrosis creates an environment that suppresses immune cells and protects the tumor from the immune system and immunotherapy. Immunotherapy can initially elicit significant therapy responses which diminish for many patients, and we believe the fibrotic barrier is a key contributor. We believe Aramchol’s novel LNP treatment could potentially make immunotherapy and other standard of care for liver and GI cancer therapies, work better for more patients for longer time and better results.”

 

Ronen Eavri Chief Executive Officer of Barcode-Nanotech commented: “Building on our earlier work with Galmed to deliver Aramchol to the brain and the heart, we are now applying our proprietary lipid library and in vivo, AI-based screening platform, including our tumor-targeting LNP technology, to the development of an Aramchol LNP formulation directed to the tumor microenvironment of liver and GI cancers. By selectively reaching the cells that drive fibrosis, we hope to help immunotherapy and other standard-of-care treatments work for more patients.”

 

About Eocene (formerly Galmed Pharmaceuticals)

 

Eocene Ltd. (NASDAQ: EOCN) is a GI-focused medtech and biopharmaceutical company headquartered in Givatayim, Israel, dedicated to advancing innovative solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. The Company is building a diversified platform that combines medical devices, therapeutics and enabling technologies to address significant unmet clinical needs and improve patient outcomes. Eocene’s wholly owned subsidiary, Galmed Research & Development develop Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers. Eocene’s wholly owned medtech subsidiary Colospan Ltd., is a commercial-stage medical device company developing solutions designed to transform postoperative colorectal care. Its flagship product, CG-100, is an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas, offering a less invasive alternative to current surgical practice. CG-100 has received FDA Breakthrough Device Designation, is CE marked under the European Union Medical Device Regulation and is approved for investigational use in the United States under an FDA-approved IDE. The device is not approved for commercial use in the United States.

 

About Barcode Nanotech Ltd.:

 

Barcode Nanotech develops delivery solutions for RNA & DNA therapies through a unique multiplexed discovery platform. The Company’s proprietary NeoRNA™ Targeting Technology enables efficient discovery and optimization of lipid-based nanoparticles (LNPs) through in silico & in vivo mass-screening. The solution combines the design of thousands of new lipids and LNPs, advanced AI tools and in vivo barcoding-based biodistribution analysis at a single cell resolution. Using this platform, Barcode has developed unique LNPs that can direct RNA and other therapies to tumors and to cells in the brain, kidney, lungs and additional target organs. Barcode has an in-house lead drug development program and concurrently collaborates with biopharma companies to develop new therapies.

 

For more information, visit www.eocn.com and www.barcode-nano.com

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to: the design, potential benefits and therapeutic potential of the Aramchol LNP formulation, including its potential to redirect Aramchol’s biodistribution to the tumor microenvironment, inhibit cells that drive fibrosis and enhance the effectiveness of immunotherapy and other standard-of-care therapies for liver and GI cancers; the progress, timing and results of preclinical research and any future clinical development of the Aramchol LNP formulation; the continuation and success of the collaboration between Galmed and Barcode Nanotech; the potential evaluation of Aramchol in oncology indications; the potential benefits of CG-100 and the progress and results of Colospan’s ongoing U.S. pivotal study of CG-100; the timing, extent and potential generation of future revenues; the expected benefits arising from the acquisition of Colospan; the Company’s ability to execute its strategy and growth initiatives, including using its existing capital resources; and the Company’s future business, operations, financial condition, prospects and objectives. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the risk that preclinical results may not be predictive of results in humans; the risk that the Aramchol LNP formulation may not achieve its intended biodistribution, safety or efficacy, or may not advance into clinical development; the risk that the collaboration with Barcode Nanotech may be delayed, modified or terminated; our inability to recognize the anticipated benefits of the acquisition of Colospan; expectations with respect to future performance and growth of Colospan; the development and approval of the use of Aramchol or any other product candidate for indications outside of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in combination therapy; the timing and cost of any pre-clinical or clinical trials of CG-100, Aramchol or any other medical device or product candidate we develop; completion and receiving favorable results of any pre-clinical or clinical trial; regulatory action with respect to CG-100, Aramchol or any other medical device or product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Agency, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; the commercial launch and future sales of CG-100, Aramchol and any future medical devices or product candidates; our ability to comply with all applicable post-market regulatory requirements for CG-100, Aramchol, or any other medical device or product candidate in the countries in which we seek to market the product; our ability to achieve favorable pricing for CG-100, Aramchol, or any medical device or other product candidate; third-party payor reimbursement for CG-100, Aramchol, or any other medical device or product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market adoption of CG-100 Aramchol or any other medical device or product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of CG-100, Aramchol or any other medical device or product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our CG-100 or product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; and the security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel. We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 31, 2026 in greater detail under the heading “Risk Factors” and the additional risk factors relating to the business of Colospan Ltd. in the section entitled “Risk Factors” in our Report on Form 6-K filed with the SEC on June 8, 2026. Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by law. In evaluating forward-looking statements, you should consider these risks and uncertainties.

 

Investor and Media contact: +972-3-693-8448, investor.relations@eocn.com

 

 

 

Filing Exhibits & Attachments

1 document

Keep reading